Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM.

Blood. 2019 Dec 16. pii: blood.2019002140. doi: 10.1182/blood.2019002140. [Epub ahead of print]

2.

Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia.

Gelfand JM, Greenfield AL, Barkovich M, Mendelsohn BA, Van Haren K, Hess CP, Mannis GN.

Brain. 2020 Feb 1;143(2):503-511. doi: 10.1093/brain/awz390.

PMID:
31840744
3.

Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.

Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL.

Biol Blood Marrow Transplant. 2020 Jan;26(1):189-196. doi: 10.1016/j.bbmt.2019.08.022. Epub 2019 Sep 5.

PMID:
31493541
4.

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM; OCN, Hammond L, Ogba N.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028.

PMID:
31200351
5.

Maintenance lenalidomide in primary CNS lymphoma.

Rubenstein JL, Geng H, Vu K, Mannis G, Formaker P, Hwang J, Munster PN, Damato B.

Ann Oncol. 2019 Aug 1;30(8):1397-1398. doi: 10.1093/annonc/mdz142. No abstract available.

PMID:
31046114
6.

Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.

Vu K, Mannis G, Hwang J, Geng H, Rubenstein JL.

Br J Haematol. 2019 Jul;186(1):180-183. doi: 10.1111/bjh.15787. Epub 2019 Feb 3. No abstract available.

PMID:
30714128
7.

Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.

Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1218-1224. doi: 10.1016/j.bbmt.2019.01.028. Epub 2019 Jan 30.

PMID:
30708189
8.

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant.

Rahmat LT, Nguyen A, Abdulhaq H, Prakash S, Logan AC, Mannis GN.

Case Rep Hematol. 2018 Aug 26;2018:6092646. doi: 10.1155/2018/6092646. eCollection 2018.

9.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

10.

Discussion on reply to Foley et al., 'Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?'

Mannis GN.

Cancer Genet. 2018 Jan;220:77-78. doi: 10.1016/j.cancergen.2017.11.002. Epub 2017 Nov 27. No abstract available.

PMID:
29246709
11.

Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?

Foley N, Van Ziffle J, Yu J, Qi Z, Grenert JP, Yeh I, Bastian B, Kogan S, Mannis GN.

Cancer Genet. 2017 Oct;216-217:74-78. doi: 10.1016/j.cancergen.2017.07.002. Epub 2017 Jul 31.

PMID:
29025598
12.

Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.

Gupta NK, Wang CC, Mannis GN, Yu JJ, Rubenstein JL.

Leuk Lymphoma. 2017 Nov;58(11):2748-2751. doi: 10.1080/10428194.2017.1312374. Epub 2017 Apr 10. No abstract available.

13.

Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant.

Eckhert EE, Schoenbeck KL, Galligan D, McNey LM, Hwang J, Mannis GN.

Bone Marrow Transplant. 2017 Jun;52(6):929-931. doi: 10.1038/bmt.2017.41. Epub 2017 Mar 13. No abstract available.

PMID:
28287642
14.

Long-term survival in AIDS-related primary central nervous system lymphoma.

Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL.

Neuro Oncol. 2017 Jan;19(1):99-108. doi: 10.1093/neuonc/now155. Epub 2016 Aug 30.

15.

Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1974-1982. doi: 10.1016/j.bbmt.2016.08.014. Epub 2016 Aug 17.

16.

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.

Mannis GN, Martin TG 3rd, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1030-1036. doi: 10.1016/j.bbmt.2016.02.004. Epub 2016 Feb 16.

17.

Paraproteinemic keratopathy as the presenting sign of hematologic malignancy.

Mannis TE, Mannis GN, Waterhouse EG, Aldave AJ, Rose-Nussbaumer J.

Am J Hematol. 2016 Sep;91(9):961-2. doi: 10.1002/ajh.24327. Epub 2016 Apr 13. No abstract available.

18.

Inferior vena cava filter thrombosis.

Byrne M, Mannis GN, Nair J, Andreadis C.

Clin Case Rep. 2015 Dec 16;4(2):162-4. doi: 10.1002/ccr3.418. eCollection 2016 Feb.

19.

The transfusion tether: Bridging the gap between end-stage hematologic malignancies and optimal end-of-life care.

Mannis GN, McNey LM, Gupta NK, Gross DM.

Am J Hematol. 2016 Jun;91(4):364-5. doi: 10.1002/ajh.24294. Epub 2016 Feb 9. No abstract available.

20.

Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.

Mannis GN, Martin TG 3rd, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C.

Leuk Lymphoma. 2016 Jul;57(7):1560-6. doi: 10.3109/10428194.2015.1088646. Epub 2016 Jan 4.

PMID:
26490487

Supplemental Content

Loading ...
Support Center